Science Events in Boston
Stay up-to-date with all of the life science events taking place in the Greater Boston area with the Science in Boston events calendar! From academia to industry and biotech to pharma, our events calendar is your complete source for life science conferences, symposiums, networking, and workshops in Boston. We even cover science pub nights and science fundraisers!
If you’re interested in promoting your life science event on the Science in Boston events calendar, please use our event submission form.
- This event has passed.
Industry Career Chat with Flare Therapeutics
September 30, 2021 - 4:00 pm - 5:00 pm
They are very excited to be hosting Jenny Mertz, Ph.D, Senior Director, Biology, and Robert Sims, Ph.D., CSO and co-founder of Flare Therapeutics!
Jenny’s Flare characteristics: Moving programs forward with data-driven decisions and having fun doing it!
Jenny has experience ranging from early target discovery, to supporting phase 3 clinical development in small molecule oncology therapeutics, while working in discovery biology and leading translational biology over the past 12+ years. Over this time, Jenny has moved various projects forward with rigor and objectiveness, working on cross-functional teams to build strong data packages to give the best chance for success, from early target discovery to translationally focused efforts.
Robert’s Flare characteristics: Fostering communication and collaboration while having a blast.
With 20+ years of experience in the transcription field, including 10+ years in the drug discovery of gene control, Robert is passionate about working with diverse and talented teams to discover and develop novel transcription factor medicines. As a founding scientist of Constellation Pharmaceuticals, he feels fortunate to have experienced and contributed to nearly all aspects of company creation— from concept to becoming a public company, with multiple programs in clinical development. While at Constellation, Robert led the discovery and translational efforts for Pelabresib, a BET bromodomain inhibitor now in phase 3 clinical development for the treatment of myelofibrosis.
